These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 20706150)

  • 101. Treatment of chronic posterior laryngitis with esomeprazole.
    Vaezi MF; Richter JE; Stasney CR; Spiegel JR; Iannuzzi RA; Crawley JA; Hwang C; Sostek MB; Shaker R
    Laryngoscope; 2006 Feb; 116(2):254-60. PubMed ID: 16467715
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies.
    Laine L; Katz PO; Johnson DA; Ibegbu I; Goldstein MJ; Chou C; Rossiter G; Lu Y
    Aliment Pharmacol Ther; 2011 Jan; 33(2):203-12. PubMed ID: 21114792
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Effects of 6-12 months of esomeprazole treatment on the gastric mucosa.
    Genta RM; Rindi G; Fiocca R; Magner DJ; D'Amico D; Levine DS
    Am J Gastroenterol; 2003 Jun; 98(6):1257-65. PubMed ID: 12818266
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group.
    Hassall E; Israel D; Shepherd R; Radke M; Dalväg A; Sköld B; Junghard O; Lundborg P
    J Pediatr; 2000 Dec; 137(6):800-7. PubMed ID: 11113836
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.
    Kiljander TO; Harding SM; Field SK; Stein MR; Nelson HS; Ekelund J; Illueca M; Beckman O; Sostek MB
    Am J Respir Crit Care Med; 2006 May; 173(10):1091-7. PubMed ID: 16357331
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy.
    Shaheen NJ; Denison H; Björck K; Silberg DG
    Am J Gastroenterol; 2013 Apr; 108(4):529-34. PubMed ID: 23318482
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study.
    Kulig M; Nocon M; Vieth M; Leodolter A; Jaspersen D; Labenz J; Meyer-Sabellek W; Stolte M; Lind T; Malfertheiner P; Willich SN
    J Clin Epidemiol; 2004 Jun; 57(6):580-9. PubMed ID: 15246126
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Esomeprazole reduces gastroesophageal reflux after beer consumption in healthy volunteers.
    Franke A; Hepp C; Harder H; Beglinger C; Singer MV
    Scand J Gastroenterol; 2008; 43(12):1425-31. PubMed ID: 18924018
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy.
    Thitiphuree S; Talley NJ
    Int J Clin Pract; 2000 Oct; 54(8):537-41. PubMed ID: 11198734
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Gastroesophageal reflux disease: new treatments.
    Katz PO
    Rev Gastroenterol Disord; 2002; 2(2):66-74. PubMed ID: 12122962
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Effect of antireflux treatment on asthma exacerbations in nonatopic children.
    Khoshoo V; Haydel R
    J Pediatr Gastroenterol Nutr; 2007 Mar; 44(3):331-5. PubMed ID: 17325553
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial.
    Flook NW; Moayyedi P; Dent J; Talley NJ; Persson T; Karlson BW; Ruth M
    Am J Gastroenterol; 2013 Jan; 108(1):56-64. PubMed ID: 23147520
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.
    Reichel O; Dressel H; Wiederänders K; Issing WJ
    Otolaryngol Head Neck Surg; 2008 Sep; 139(3):414-20. PubMed ID: 18722223
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Esomeprazole: update and clinical review.
    Baker DE
    Rev Gastroenterol Disord; 2002; 2(4):189-99. PubMed ID: 12481170
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Efficacy of esomeprazole in patients with acid-peptic disorders.
    Beck J
    Gastroenterol Nurs; 2004; 27(2):44-9. PubMed ID: 15082946
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease.
    Bayerdörffer E; Bigard MA; Weiss W; Mearin F; Rodrigo L; Dominguez Muñoz JE; Grundling H; Persson T; Svedberg LE; Keeling N; Eklund S
    BMC Gastroenterol; 2016 Apr; 16():48. PubMed ID: 27080034
    [TBL] [Abstract][Full Text] [Related]  

  • 117. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease.
    Norman Hansen A; Bergheim R; Fagertun H; Lund H; Moum B
    Int J Clin Pract; 2005 Jun; 59(6):665-71. PubMed ID: 15924594
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn.
    Johnsson F; Hatlebakk JG; Klintenberg AC; Román J
    Scand J Gastroenterol; 2003 Apr; 38(4):347-53. PubMed ID: 12739705
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Scheiman JM; Herlitz J; Veldhuyzen van Zanten SJ; Lanas A; Agewall S; Nauclér EC; Svedberg LE; Nagy P
    J Cardiovasc Pharmacol; 2013 Mar; 61(3):250-7. PubMed ID: 23188121
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study.
    Li J; Zhao J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
    Clin Ther; 2006 Mar; 28(3):419-27. PubMed ID: 16750456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.